Inhibitory effects of melatonin on titanium particle-induced inflammatory bone resorption and osteoclastogenesis via suppression of NF-κB signaling
Source abstract
Abstract
Wear debris-induced peri-implant osteolysis challenges the longevity of implants. The host response to wear debris causes chronic inflammation, promotes bone resorption, and impairs bone formation. We previously demonstrated that melatonin enhances bone formation and attenuates wear debris-induced bone loss in vivo. However, whether melatonin inhibits chronic inflammation and bone resorption at sites of wear debris-induced osteolysis remains unclear. In this study, we examined the potential inhibitory effects of melatonin on titanium particle-induced inflammatory osteolysis in a murine calvarial model and on RANKL-induced osteoclastic formation in bone marrow-derived macrophages. We found that the exogenous administration of melatonin significantly inhibited wear debris-induced bone resorption and the expression of inflammatory cytokines in vivo. Additionally, melatonin inhibited RANKL-induced osteoclast differentiation, F-actin ring formation, and osteoclastic resorption in a concentration-dependent manner in vitro. We also showed that melatonin blocked the phosphorylation of IκB-α and p65, but not IKKα, and significantly inhibited the expression of NFATc1 and c-Fos. However, melatonin had no effect on MAPK or PI3K/AKT signaling pathways. These results provide novel mechanistic insight into the anti-inflammatory and anti-bone resorptive effects of melatonin on wear debris-induced bone loss and provide an evidence-based rationale for the protective effects of melatonin as a treatment for peri-implant osteolysis. Statement of significance Wear debris-induced chronic inflammation, osteoclastic activation and osteoblastic inhibition have been identified as critical factors of peri-implant bone loss. We previously demonstrated that melatonin, a bioactive indolamine secreted mainly by the pineal gland, activates Wnt/β-catenin signaling pathway and enhances bone regeneration at osteolytic site in vivo. In the current study, we further demonstrated that melatonin significantly suppresses wear debris-induced bone resorption and inflammatory cytokine expression in vivo. In addition, melatonin inhibits receptor activator of nuclear factor kappa-B ligand induced osteoclast formation and osteoclastic bone resorption in vitro. Meanwhile, we found that melatonin mediates its anti-inflammation and anti-bone resorption effects by abrogating nuclear factor kappa-B activation. These results further support the protective effects of melatonin on wear debris-induced peri-implant bone loss, and strongly suggest that melatonin could be considered as a potential candidate for the prevention and treatment of wear debris-induced osteolysis and subsequent aseptic loosening.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Circadian rhythm and melatonin · Selenium in Biological Systems · Spaceflight effects on biology
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (36)
Show source-provided references
1. Long-term results of Charnley-Kerboull hip arthroplasty in patients younger than 50 years10.1097/00003086-200401000-00018 ↗
2. The biology of aseptic osteolysis10.1097/BLO.0b013e31804b4147 ↗
3. Effects of orthopaedic wear particles on osteoprogenitor cells10.1016/j.biomaterials.2006.08.023 ↗
4. Icariin protects against titanium particle-induced osteolysis and inflammatory response in a mouse calvarial model10.1016/j.biomaterials.2015.04.048 ↗
5. Cytokines and osteolysis around total hip prostheses10.1006/cyto.2000.0753 ↗
6. Tumor necrosis factor-alpha mediates orthopedic implant osteolysis10.1016/S0002-9440(10)65266-2 ↗
7. Melatonin: pharmacology functions and therapeutic benefits10.2174/1570159X14666161228122115 ↗
8. Novel bromomelatonin derivatives suppress osteoclastic activity and increase osteoblastic activity: implications for the treatment of bone diseases10.1111/j.1600-079X.2007.00533.x ↗
9. Melatonin suppresses osteoclastic and osteoblastic activities in the scales of goldfish10.1034/j.1600-079X.2002.02953.x ↗
10. Melatonin improves bone mineral density at the femoral neck in postmenopausal women with osteopenia: a randomized controlled trial10.1111/jpi.12252 ↗
11. Melatonin effects on bone: potential use for the prevention and treatment for osteopenia, osteoporosis, and periodontal disease and for use in bone-grafting procedures10.1111/jpi.12116 ↗
12. Clinical and radiographic evaluation of immediate loaded dental implants with local application of melatonin: a preliminary randomized controlled clinical trial10.1563/aaid-joi-D-14-00277 ↗
13. Melatonin attenuates titanium particle-induced osteolysis via activation of Wnt/beta-catenin signaling pathway10.1016/j.actbio.2017.01.034 ↗
14. Protection against titanium particle induced osteolysis by cannabinoid receptor 2 selective antagonist10.1016/j.biomaterials.2009.11.069 ↗
15. The prevention of titanium-particle-induced osteolysis by OA-14 through the suppression of the p38 signaling pathway and inhibition of osteoclastogenesis10.1016/j.biomaterials.2014.06.055 ↗
16. Melatonin at pharmacologic doses increases bone mass by suppressing resorption through down-regulation of the RANKL-mediated osteoclast formation and activation10.1359/jbmr.2002.17.7.1219 ↗
17. Quantification of tartrate resistant acid phosphatase distribution in mouse tibiae using image analysis10.1080/10520290310001646668 ↗
18. Theaflavin-3,3'-digallate represses osteoclastogenesis and prevents wear debris-induced osteolysis via suppression of ERK pathway10.1016/j.actbio.2016.11.022 ↗
19. Oestrogen deficiency modulates particle-induced osteolysis10.1186/ar3381 ↗
20. RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta10.1038/416744a ↗
21. Osteoclasts: what do they do and how do they do it?10.2353/ajpath.2007.060834 ↗
22. Mechanistic aspects of NF-kappa B regulation: the emerging role of phosphorylation and proteolysis10.1016/1074-7613(95)90112-4 ↗
23. Functions of nuclear factor kappaB in bone10.1111/j.1749-6632.2009.05315.x ↗
24. Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts10.1016/S0006-291X(03)00695-8 ↗
25. Requirement for NF-kappaB in osteoclast and B-cell development10.1101/gad.11.24.3482 ↗
26. Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB210.1038/nm1197-1285 ↗
27. NF-kB signaling blockade abolishes implant particle-induced osteoclastogenesis10.1016/S0736-0266(03)00156-6 ↗
28. NF-kappaB decoy oligodeoxynucleotide mitigates wear particle-associated bone loss in the murine continuous infusion model10.1016/j.actbio.2016.05.038 ↗
29. Melatonin inhibits MMP-9 transactivation and renal cell carcinoma metastasis by suppressing Akt-MAPKs pathway and NF-kappaB DNA-binding activity10.1111/jpi.12308 ↗
30. Melatonin protects methamphetamine-induced neuroinflammation through NF-kappaB and Nrf2 pathways in glioma cell line10.1007/s11064-015-1613-2 ↗
31. Melatonin attenuates D-galactose-induced memory impairment, neuroinflammation and neurodegeneration via RAGE/NF-K B/JNK signaling pathway in aging mouse model10.1111/jpi.12194 ↗
32. Melatonin modulates microsomal PGE synthase 1 and NF-E2-related factor-2-regulated antioxidant enzyme expression in LPS-induced murine peritoneal macrophages10.1111/bph.12428 ↗
33. Melatonin: a pleiotropic molecule regulating inflammation10.1016/j.bcp.2010.07.041 ↗
34. Comparison of the roles of IL-1, IL-6, and TNFalpha in cell culture and murine models of aseptic loosening10.1016/j.bone.2006.12.053 ↗
35. Strontium ranelate inhibits titanium-particle-induced osteolysis by restraining inflammatory osteoclastogenesis in vivo10.1016/j.actbio.2014.07.025 ↗
36. Melatonin treatment normalizes plasma pro-inflammatory cytokines and nitrosative/oxidative stress in patients suffering from Duchenne muscular dystrophy10.1111/j.1600-079X.2010.00752.x ↗